FDA’s OPDP Publishes Three Letters Furthering the Crackdown on DTC Advertising

Direct-to-consumer prescription drug advertising has always lived in a tense little neighborhood: one house belongs to education, the other belongs to persuasion, and the zoning rules are written by the FDA. In late 2025, the Office of Prescription Drug Promotion, better known as OPDP, made it crystal clear that it plans to patrol that neighborhood with a much brighter flashlight. Three closely watched untitled letters involving Cobenfy, Tevimbra, and Nexlizet did more than swat at a few ads. Together, they showed that the FDA is scrutinizing not just what drug marketers say, but the entire impression an ad leaves behind.

That distinction matters. In modern pharmaceutical promotion, the “message” is no longer just a line of copy or a legal super at the bottom of the screen. It is the vibe. It is the pace. It is the testimonial. It is the cartoon cholesterol creature doing synchronized swimming in your artery. And if that overall impression suggests more benefit, less risk, broader use, or a happier ending than the data can actually support, OPDP appears ready to pounce.

So yes, these three letters matter. They are not random scoldings buried in a regulatory filing cabinet. They are a roadmap for what OPDP now sees as high-risk conduct in DTC drug promotion: overstated efficacy, incomplete indication language, omitted or minimized risk information, and creative presentation choices that distract viewers from the major safety statement. For pharma brands, agencies, media teams, and legal-review committees, this is the regulatory equivalent of the teacher walking into class, tapping the whiteboard, and saying, “There will be a test.”

Why these three OPDP letters matter right now

The FDA’s broader crackdown on deceptive drug advertising did not appear out of nowhere. In September 2025, FDA and HHS publicly announced a harder line on direct-to-consumer promotion, emphasizing fair balance, meaningful risk disclosure, and closer scrutiny across TV, digital, and social media. The December letters then gave the industry something more concrete than speeches and press releases: actual enforcement examples showing where FDA believes the line now sits.

What makes these letters especially important is their variety. One targets a TV ad for schizophrenia treatment. One goes after virtual meeting backgrounds for an oncology drug. One zeroes in on a connected-TV cholesterol spot with animated visuals and comparative messaging. Different products, different formats, different disease areas. Same central lesson: if the communication promotes a prescription drug, OPDP expects the ad to be truthful, balanced, and consistent with the FDA-approved labeling. Cute formatting does not get a hall pass.

A quick primer: what OPDP does and why an untitled letter still hurts

OPDP sits within FDA’s Center for Drug Evaluation and Research and reviews prescription drug advertising and promotional labeling. Its mission is simple on paper and messy in practice: make sure prescription drug promotion is truthful, balanced, and accurately communicated. The office reviews launch materials, monitors complaints, evaluates claims against labeling and clinical data, and issues compliance letters when it believes a promotion crosses the line.

An untitled letter is not the same as a warning letter, but no one in pharma treats it like a friendly Post-it note. FDA uses untitled letters for violations that may not meet the warning-letter threshold, yet the agency still expects prompt correction. In other words, it is lighter than a warning letter in form, but very serious in effect. A posted untitled letter can trigger internal fire drills, agency rework, media pulls, MLR reviews, and a lot of very grim coffee refills.

Letter one: Cobenfy and the danger of saying more than the studies proved

The Cobenfy letter is a great example of how OPDP reads beyond the literal wording of an ad. The TV spot suggested that Cobenfy delivered improvement “across a range of schizophrenia symptoms,” while pairing that message with visuals linking both positive and negative symptoms. That was the problem. FDA said the pivotal trials were built around overall symptom change, not separate proof that the drug improved positive and negative symptoms as distinct categories.

That may sound like hair-splitting, but from OPDP’s perspective it is a classic substantiation issue. If the trial measured total score change, a marketer cannot automatically slice that overall result into narrower, consumer-facing claims about specific symptom clusters. The agency also objected to language implying Cobenfy works for people who “still have symptoms,” reading that as an unsupported suggestion about treatment-refractory schizophrenia. Then came another strike: the ad reportedly said Cobenfy is “not an antipsychotic,” which FDA rejected because drug classification depends on therapeutic use and effect, not just mechanism of action.

And then, because this is 2025 and nothing is allowed to be boring, FDA also criticized the spot’s lively visuals during the major statement. Skateboarding, petting dogs, DJ imagery, fast cuts: all of that may help a brand feel current and human, but OPDP’s message was blunt. If those visuals pull attention away from risk information, they are not harmless style. They are part of the violation.

Letter two: Tevimbra proves that even a Teams background can be promotional labeling

If anyone in pharma still thought a virtual background was just office décor with branding, the Tevimbra letter ruined that fantasy. OPDP objected to two Teams backgrounds that made claims about Tevimbra and “upper GI cancers” without including risk information and without adequately presenting the full, FDA-approved indication. That is a big compliance message hiding inside a seemingly small format.

The genius and terror of this letter is that it widens the field. Promotional risk does not live only in 60-second TV spots and glossy banner ads. It can show up in the branded wallpaper behind a speaker on a video call, on a conference slide, in an email signature, or on a sales aid that somebody swears is “just visual support.” Once a communication suggests a use or benefit of a prescription drug, OPDP may treat it like promotion. And if it is promotion, fair balance and material facts are back on the table.

That makes the Tevimbra letter a practical nightmare for any organization that separated “real ads” from all the supporting brand furniture around them. FDA basically said: sorry, your wallpaper has obligations now. Welcome to compliance.

Letter three: Nexlizet and the problem with “only,” “proven,” and animated artery theater

The Nexlizet letter reads like a warning label for superlatives. OPDP challenged the ad’s claim that the bempedoic acid ingredient in Nexlizet was the “only” nonstatin approved to lower bad cholesterol and reduce the risk of heart attack in statin-intolerant patients. FDA said that was misleading because certain PCSK9 inhibitors also have approved LDL-lowering and cardiovascular-risk-reduction claims. In plain English, the ad used exclusivity language where exclusivity did not truly exist.

This is one of the oldest mistakes in marketing and one of the most tempting. “Only,” “best,” “proven,” and “can’t take X? choose us” are the words that make copywriters smile and regulatory lawyers reach for ibuprofen. OPDP’s position here reinforces a strict view: comparative or exclusive claims must be exceptionally well supported, narrowly framed, and fully aligned with the approved labeling landscape. If there is a clinically relevant alternative with similar approved claims, the “only” argument starts wobbling fast.

Then there were the visuals. FDA took issue with the cartoon-like “lipid lurkers” cavorting through an artery during the major statement, saying the imagery interfered with comprehension of the risk information. This may sound funny, and honestly it is a little funny, but the regulatory point is serious. OPDP is not evaluating creative execution in a vacuum. It is asking whether the ad’s entertainment value undercuts risk understanding. If the answer is yes, your adorable artery goblins may become Exhibit A.

The bigger pattern: OPDP is regulating net impression, not just fine print

Put these three letters together and a consistent theory emerges. OPDP is not merely counting whether a risk sentence appears somewhere in the ad. It is judging net impression. Does the ad imply a broader patient population than the trials support? Does it hint at symptom relief not specifically demonstrated? Does it simplify an indication so aggressively that material limitations disappear? Does it technically include risk information while simultaneously distracting the viewer into oblivion?

This approach lines up with long-standing FDA principles on fair balance and misleading promotion, but the recent enforcement posture makes those principles feel newly alive. The agency is also operating in a regulatory environment shaped by more recent guidance, including the final rule requiring the major statement in DTC TV and radio ads to be presented in a clear, conspicuous, and neutral manner, plus guidance on consumer-friendly presentation of quantitative efficacy and risk information. The direction of travel is obvious: clearer risk communication, fewer winks and nudges, and much less patience for “overall messaging” that outruns the evidence.

What pharma marketers, agencies, and review committees should do next

1. Audit implied claims, not just explicit ones

If your ad does not literally say something, that does not mean OPDP thinks you avoided the claim. Symptom groupings, before-and-after storytelling, emotional transformation arcs, and visuals that imply a return to normal life can all create unsupported efficacy impressions. Regulatory review needs to ask, “What does the audience reasonably take away?” not just “What words are on the page?”

2. Treat every branded asset like it might become evidence

Webinars, Teams backgrounds, speaker templates, event signage, social snippets, connected-TV cutdowns, and internal-external hybrid assets all deserve promotion review if they make drug claims or suggest uses. The Tevimbra letter makes that painfully clear.

3. Stop assuming the major statement is safe just because it exists

FDA increasingly cares whether viewers can actually notice, follow, and understand the risk information. That means teams should test pacing, typography, audio clarity, contrast, motion, and distraction. A compliant script can still become a noncompliant ad if the presentation turns the risk section into background noise.

4. Be very careful with exclusivity language

Words like “only,” “first,” “proven,” and “different from everything else” are regulatory magnets. If the market landscape or label language is more nuanced than the headline suggests, the claim may not survive contact with OPDP.

Why this crackdown matters beyond the conference room

For patients, this matters because DTC advertising is not just wallpaper in the American healthcare system. It shapes awareness, expectations, and conversations in exam rooms. For clinicians, it matters because promotional messaging can influence what questions patients ask and which products they request. For manufacturers, it matters because the old idea that clever formatting can soften or outrun regulatory requirements is aging badly.

The real story behind these letters is not that FDA suddenly hates creativity. It is that the agency increasingly treats creativity as part of the claim environment. If the ad is memorable because it is vivid, emotional, fast-moving, or visually playful, OPDP wants to know whether those same features also distort how benefits and risks are understood. That is the new stress test.

Experience from the front lines: what this crackdown feels like in practice

In the real world, an OPDP crackdown does not arrive as an abstract policy trend. It shows up on a Tuesday morning in a brand team’s inbox, and suddenly everyone who was joking in the kickoff meeting is talking like they are defusing a submarine. The copy team says the claim is technically true. The medical reviewer says technically true is not the same thing as contextually fair. The legal team says “net impression” three times in one sentence. The agency creative director stares at a storyboard that took six weeks to sell through and realizes the dancing molecule, the hopeful patient montage, and the triumphant music cue may all now count as liabilities instead of assets.

That is the lived experience of these OPDP letters. A marketer may see a compelling patient story. OPDP may see an implied promise of restored normalcy. A designer may see a clean disease-state shorthand. OPDP may see an incomplete indication. A digital producer may think a branded Teams background is just visual consistency. OPDP may see a promotional communication missing risk information. Nobody in the room is necessarily acting in bad faith, but the enforcement trend suggests that good intentions are no longer a reliable shield.

There is also a very specific emotional rhythm to this kind of compliance pressure. First comes disbelief: “Really? They care about that?” Then comes the group reread. Then the phrase “out of an abundance of caution” enters the chat, which is corporate for “we are deleting half this campaign before lunch.” By the time the med-legal-regulatory committee reconvenes, every flashy adjective in the deck suddenly looks like it was written by a stranger. “Transformative,” “breakthrough,” “across a range,” “helps you get back to life” all of it starts to feel less like marketing and more like potential evidence.

From the patient side, though, the experience is different. Most viewers do not watch a DTC ad with a highlighter and a copy of the prescribing information. They watch while making dinner, folding laundry, or scrolling during a commercial break. They absorb mood faster than nuance. They remember confidence, movement, color, relief, and the emotional promise that life could get easier. That is exactly why OPDP keeps focusing on the full communication environment. The agency knows consumers are often processing the ad as a story before they process it as regulated speech.

And for healthcare professionals, the aftermath can be frustrating in a quieter way. They become the ones who have to translate the ad back into reality. A patient walks in asking whether a drug works on every symptom, whether it is right after other treatments fail, or whether the side effects are “probably not a big deal” because the ad made the whole thing look like a lifestyle upgrade with a legal disclaimer attached. That gap between impression and evidence is where the clinical conversation gets heavier.

So the experience of this crackdown is not just more redlines. It is a reset in how pharmaceutical promotion gets imagined, built, and defended. Brand teams now have to think less like ad makers chasing recall and more like evidence translators working in public. That may feel restrictive, but it is also clarifying. If a campaign cannot survive close scrutiny of its claims, visuals, pacing, and omissions, it probably was not as strong as everyone hoped. OPDP is essentially forcing the industry to make promotion that can hold up in daylight, not just under studio lighting.

Final takeaway

These three OPDP letters are not isolated compliance hiccups. They are a sharp, practical statement about where FDA enforcement is headed in DTC drug advertising. Unsupported symptom claims, incomplete indication language, missing risk information, and distracting creative execution are all squarely in the crosshairs. The agency is looking at entire consumer takeaways, not isolated words clipped from a transcript.

For pharma marketers, the message is simple even if the work is not: say what the label and the evidence support, show risks in a way people can actually absorb, and never assume a slick format can rescue a weak claim. In this environment, the safest creative trick might be the least glamorous one of all: clarity.